Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Alteration of drug-protein binding in renal disease.

Literature DB >> 6705423

Alteration of drug-protein binding in renal disease.

Abstract

The protein binding of acidic drugs but not basic drugs is decreased in serum from patients with poor renal function. This decreased binding is due to the retention of compounds that displace drugs from their binding sites on albumin. Phenytoin and valproic acid are the 2 drugs that require a change in the values for therapeutic levels to allow for this decreased binding.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1984 PMID： 6705423 DOI： 10.2165/00003088-198400091-00003

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

88 in total

1. The protein binding of diazepam and N-demethyldiazepam in patients with poor renal function.

Authors: L Kangas; J Kanto; J Forsström; E Iisalo
Journal: Clin Nephrol Date: 1976-03 Impact factor: 0.975

2. Decreased drug binding by serum albumin during renal failure.

Authors: D S Campion
Journal: Toxicol Appl Pharmacol Date: 1973-07 Impact factor: 4.219

3. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors: M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal: N Engl J Med Date: 1971-07-29 Impact factor: 91.245

4. Abnormal pharmacokinetics of phenytoin in a patient with uraemia.

Authors: I Odar-Cederlöf; P Lunde; F Sjöqvist
Journal: Lancet Date: 1970-10-17 Impact factor: 79.321

5. Renal function, protein binding and pharmacological response to diazoxide.

Authors: R M Pearson; A M Breckenridge
Journal: Br J Clin Pharmacol Date: 1976-02 Impact factor: 4.335

6. Pentobarbital elimination in patients with poor renal function.

Authors: M M Reidenberg; D T Lowenthal; W Briggs; M Gasparo
Journal: Clin Pharmacol Ther Date: 1976-07 Impact factor: 6.875

7. Kinetics of salicylate elimination by anephric patients.

Authors: D T Lowenthal; W A Briggs; G Levy
Journal: J Clin Invest Date: 1974-11 Impact factor: 14.808

8. Pharmacokinetics of azlocillin in persons with normal and impaired renal functions.

Authors: P Fiegel; K Becker
Journal: Antimicrob Agents Chemother Date: 1978-09 Impact factor: 5.191

9. Phenytoin binding to partially purified albumin in renal disease.

Authors: D W Kinniburgh; N D Boyd
Journal: Clin Pharmacol Ther Date: 1981-02 Impact factor: 6.875

10. Drug binding defect of uraemic plasma: unlikely involvement of carbamoylated albumin.

Authors: L S Clegg; W E Lindup
Journal: Biochem Pharmacol Date: 1982-09-01 Impact factor: 5.858

38 in total

Review 1. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors: Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal: Clin Pharmacokinet Date: 2012-08-01 Impact factor: 6.447

Review 2. Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors: G M Pacifici; A Viani
Journal: Clin Pharmacokinet Date: 1992-12 Impact factor: 6.447

Review 3. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors: R Zini; P Riant; J Barré; J P Tillement
Journal: Clin Pharmacokinet Date: 1990-09 Impact factor: 6.447

Review 4. Pharmacokinetics of antimicrobial agents in organ function impairment. A review.

Authors: R Janknegt
Journal: Pharm Weekbl Sci Date: 1990-08-24

Review 5. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.

Authors: D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal: Antimicrob Agents Chemother Date: 1991-10 Impact factor: 5.191

6. The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment.

Authors: A Viani; G Rizzo; M Carrai; G M Pacifici
Journal: Br J Clin Pharmacol Date: 1992-03 Impact factor: 4.335

7. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors: Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal: Eur J Clin Pharmacol Date: 2014-06-24 Impact factor: 2.953

Review 8. Plasma protein binding of drugs in pregnancy and in neonates.

Authors: L J Notarianni
Journal: Clin Pharmacokinet Date: 1990-01 Impact factor: 6.447

9. Pharmacokinetics of quinine in patients with chronic renal failure.

Authors: P Rimchala; J Karbwang; K Sukontason; V Banmairuroi; P Molunto; K Na-Bangchang
Journal: Eur J Clin Pharmacol Date: 1996 Impact factor: 2.953

10. Validation of a free phenytoin assay on Cobas c501 analyzer using calibrators from Cobas Integra free phenytoin assay by comparing its performance with fluorescence polarization immunoassay for free phenytoin on the TDx analyzer.

Authors: Amitava Dasgupta; Bonnette Davis; Loretta Chow
Journal: J Clin Lab Anal Date: 2013-01 Impact factor: 2.352